000182712 001__ 182712
000182712 005__ 20241220120852.0
000182712 0247_ $$2doi$$a10.1111/febs.16680
000182712 0247_ $$2pmid$$apmid:36380691
000182712 0247_ $$2ISSN$$a0014-2956
000182712 0247_ $$2ISSN$$a0945-5795
000182712 0247_ $$2ISSN$$a1432-1033
000182712 0247_ $$2ISSN$$a1742-464X
000182712 0247_ $$2ISSN$$a1742-4658
000182712 0247_ $$2altmetric$$aaltmetric:138746963
000182712 037__ $$aDKFZ-2022-02870
000182712 041__ $$aEnglish
000182712 082__ $$a610
000182712 1001_ $$0P:(DE-He78)4f003c3438fa98ed8d011a2a0ef56f4e$$aKim, Martin$$b0$$eFirst author
000182712 245__ $$aPlakophilin 1 deficiency in prostatic tumors is correlated with immune cell recruitment and controls the up-regulation of cytokine expression post-transcriptionally.
000182712 260__ $$aOxford [u.a.]$$bWiley-Blackwell$$c2023
000182712 3367_ $$2DRIVER$$aarticle
000182712 3367_ $$2DataCite$$aOutput Types/Journal article
000182712 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1681198749_5542
000182712 3367_ $$2BibTeX$$aARTICLE
000182712 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000182712 3367_ $$00$$2EndNote$$aJournal Article
000182712 500__ $$aDKFZ-ZMBH Alliance / #EA:A190#LA:A190# / 2023 Apr;290(7):1907-1919
000182712 520__ $$aPlakophilin (PKP1) 1 is a member of the arm-repeat family of catenins and acts as structural component of desmosomes, which are important stabilizers of cell-cell adhesion. Besides this, PKP1 also occurs in a non-junctional, cytoplasmic form contributing to post-transcriptional regulation of gene expression. Moreover, PKP1 is expressed in prostate epithelium but its expression is frequently downregulated in prostate cancers with a more aggressive phenotype. This observation may imply a tumor-suppressive role of PKP1. We found that, in prostatic adenocarcinomas with PKP1 deficiency, the occurrence of T-cells, B-cells, macrophages and neutrophils was significantly increased. In a PKP1-deficient prostatic cancer cell line expressing IL8, these levels were statistically meaningfully reduced upon PKP1 re-expression. When analyzing prostatic PKP1-knockdown cell lines, the mRNA and protein levels of additional cytokines, namely CXCL1 and IL6, were upregulated. The effect was rescued upon re-expression of a PKP1 RNAi-resistant form. The corresponding mRNAs were co-precipitated with cytoplasmic PKP1, indicating that they are components of PKP1-containing mRNA ribonucleoprotein particles. Moreover, the mRNA half-lives of CXCL1, IL8 and IL6 were significantly increased in PKP1-deficient cells, showing that these mRNAs were stabilized by PKP1. In an in vitro migration assay, the higher cytokine concentrations led to higher migration rates of THP1 and PBMC cells. This finding implies that PKP1 loss of expression in vivo correlates with recruitment of immune cells into the tumor area to set up a tumor-specific environment. One may speculate that this newly established tumor environment has tumor-suppressive characteristics and thereby accelerates tumor progression and metastasis.
000182712 536__ $$0G:(DE-HGF)POF4-311$$a311 - Zellbiologie und Tumorbiologie (POF4-311)$$cPOF4-311$$fPOF IV$$x0
000182712 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000182712 650_7 $$2Other$$aProstate cancer
000182712 650_7 $$2Other$$acytokine mRNA stability
000182712 650_7 $$2Other$$aimmune cell recruitment
000182712 650_7 $$2Other$$aplakophilin 1
000182712 650_7 $$2Other$$atumor environment
000182712 7001_ $$0P:(DE-He78)fc0599951db069ef9be58cd712305095$$aReidenbach, Sonja$$b1$$udkfz
000182712 7001_ $$0P:(DE-He78)b3ac108b47624a7d7947e220a0a50bfe$$aSchlechter, Tanja$$b2$$udkfz
000182712 7001_ $$0P:(DE-He78)073e36018e1b37581cfacdbbb060b771$$aRothmann, Ann Christin$$b3
000182712 7001_ $$0P:(DE-He78)18218139eec55d83cf82679934e5cd75$$aWill, Rainer$$b4$$udkfz
000182712 7001_ $$0P:(DE-He78)0c4543046185361a644540fee0dad8b1$$aHofmann, Ilse$$b5$$eLast author$$udkfz
000182712 773__ $$0PERI:(DE-600)2172518-4$$a10.1111/febs.16680$$gp. febs.16680$$n7$$p1907-1919$$tThe FEBS journal$$v290$$x0014-2956$$y2023
000182712 8767_ $$82022 (V10366)$$92022-06-23$$d2024-12-19$$eHybrid-OA$$jZahlung erfolgt
000182712 909CO $$ooai:inrepo02.dkfz.de:182712$$pVDB$$pOpenAPC$$popenCost
000182712 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)4f003c3438fa98ed8d011a2a0ef56f4e$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000182712 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)fc0599951db069ef9be58cd712305095$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000182712 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)b3ac108b47624a7d7947e220a0a50bfe$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000182712 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)073e36018e1b37581cfacdbbb060b771$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000182712 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)18218139eec55d83cf82679934e5cd75$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000182712 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)0c4543046185361a644540fee0dad8b1$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000182712 9131_ $$0G:(DE-HGF)POF4-311$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vZellbiologie und Tumorbiologie$$x0
000182712 9141_ $$y2022
000182712 915__ $$0StatID:(DE-HGF)3001$$2StatID$$aDEAL Wiley$$d2021-01-30$$wger
000182712 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2021-01-30
000182712 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2021-01-30
000182712 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2021-01-30
000182712 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-10-25
000182712 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-10-25
000182712 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2023-10-25
000182712 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2023-10-25
000182712 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bFEBS J : 2022$$d2023-10-25
000182712 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-10-25
000182712 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2023-10-25
000182712 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-10-25
000182712 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2023-10-25
000182712 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bFEBS J : 2022$$d2023-10-25
000182712 915pc $$0PC:(DE-HGF)0000$$2APC$$aAPC keys set
000182712 915pc $$0PC:(DE-HGF)0001$$2APC$$aLocal Funding
000182712 9202_ $$0I:(DE-He78)A190-20160331$$kA190$$lA190 Vaskuläre Onkologie und Metastasierung$$x0
000182712 9201_ $$0I:(DE-He78)A190-20160331$$kA190$$lA190 Vaskuläre Onkologie und Metastasierung$$x0
000182712 9201_ $$0I:(DE-He78)W170-20160331$$kW170$$lMonoklonale Antikörper$$x1
000182712 9201_ $$0I:(DE-He78)W111-20160331$$kW111$$lZelluläre Tools$$x2
000182712 9200_ $$0I:(DE-He78)A190-20160331$$kA190$$lA190 Vaskuläre Onkologie und Metastasierung$$x0
000182712 980__ $$ajournal
000182712 980__ $$aVDB
000182712 980__ $$aI:(DE-He78)A190-20160331
000182712 980__ $$aI:(DE-He78)W170-20160331
000182712 980__ $$aI:(DE-He78)W111-20160331
000182712 980__ $$aUNRESTRICTED
000182712 980__ $$aAPC